Production (Stage)
Sensei Biotherapeutics, Inc.
SNSE
$0.295
-$0.014-4.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.46% | -34.61% | -32.99% | -32.18% | -18.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.66% | -16.91% | -22.13% | -32.34% | -28.17% |
| Operating Income | 15.66% | 16.91% | 22.13% | 32.34% | 28.17% |
| Income Before Tax | 9.05% | 11.57% | 23.43% | 34.37% | 31.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.05% | 11.57% | 23.43% | 34.37% | 31.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.05% | 11.57% | 23.43% | 34.37% | 31.16% |
| EBIT | 15.66% | 16.91% | 22.13% | 32.34% | 28.17% |
| EBITDA | 15.39% | 17.46% | 22.75% | 33.16% | 28.89% |
| EPS Basic | 4.05% | 1.05% | 9.56% | 19.86% | 20.21% |
| Normalized Basic EPS | 8.34% | 6.13% | 7.80% | 18.35% | 19.48% |
| EPS Diluted | 4.05% | 1.05% | 9.56% | 19.86% | 20.21% |
| Normalized Diluted EPS | 8.34% | 6.13% | 7.80% | 18.35% | 19.48% |
| Average Basic Shares Outstanding | -5.13% | -10.19% | -14.75% | -18.06% | -13.80% |
| Average Diluted Shares Outstanding | -5.13% | -10.19% | -14.75% | -18.06% | -13.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |